Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Fungal Group Zygomycota01:29

Fungal Group Zygomycota

Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical education in low- and middle-income countries must be innovated without neglecting its foundational principles.

Frontiers in medicine·2026
Same author

Hepatitis D virus infection in sub-Saharan Africa: a scarcely studied, yet important issue.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Hepatitis C virus and HIV transmission: parenteral (including percutaneous) routes are still relevant and must receive due attention.

Frontiers in public health·2026
Same author

Overcoming structural barriers to tuberculosis treatment in Africa through digital technologies.

The Lancet. Microbe·2026
Same author

Research priorities for data science and artificial intelligence in global health: an international consensus exercise.

The Lancet. Global health·2026
Same author

HIV infection should no longer be detected at late stages in Italy.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Related Experiment Video

Updated: Jun 19, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Micafungin - the newest echinocandin.

Zelalem Temesgen1, Jason Barreto, Sandro Vento

  • 1Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu

Drugs of Today (Barcelona, Spain : 1998)
|October 28, 2009
PubMed
Summary

Micafungin, an echinocandin, shows strong activity against Candida species, including resistant strains, and is effective for invasive candidiasis. It is also being studied for Aspergillus infections and is well-tolerated.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Micafungin is an FDA-approved echinocandin antifungal.
  • It exhibits potent in vitro activity against various Candida species, including non-albicans and azole-resistant strains.
  • Clinical efficacy has been demonstrated for deep-seated Candida infections.

Purpose of the Study:

  • To review the efficacy and safety of micafungin.
  • To highlight its approved indications and potential uses.
  • To discuss its role in treating fungal infections.

Main Methods:

  • Review of in vitro data.
  • Analysis of clinical efficacy studies.
  • Examination of approved indications and adverse effects.

Main Results:

  • Micafungin demonstrates potent activity against Candida species.
  • It is effective in treating invasive and esophageal candidiasis.
  • Preliminary data suggest utility against Aspergillus species.

Conclusions:

  • Micafungin is a valuable agent for candidiasis and prophylaxis in stem cell transplant patients.
  • Its potential for treating Aspergillus infections warrants further investigation.
  • The drug is generally well-tolerated with a favorable safety profile.